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This article is a summary of the conference “Clinical and technological transition in breast
cancer” that took place in the Congress of the Spanish Society of Radiation Oncology, placed
in  Vigo (Spain) on June 21, 2013. Hugo Marsiglia and Philip Poortmanns were the speakers, the
ﬁrst  discussed about “Clinical and technological transition” and the second about “EORTC
clinical trials and protocols”.eywords:
reast cancer
adiotherapy
echnological
© 2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
science [1]. Perhaps the most attractive feature of recent tech-linical trial
.  Introduction
echnological advances lived in the ﬁeld of radiation therapy
RT), over the last decades have led us to have volume delin-
ation, dose calculation and treatment units toward much
ore  accurate treatment. With them we  get more  appropriate
adiation dose to the level we  want to treat. This unques-
ioned fact has caused that these new technologies will be
dopted as standard without demonstrating their superior-
ty in clinical trials. On the other hand, for the advance in
nowledge of volumes that should be treated, which dose
hould receive or the best suitable fractionation, we  need
o have sufﬁcient scientiﬁc evidence to support our treat-
ent protocols. In this article we review the introduction
∗ Corresponding author at: Radiation Oncology Department, Hospital de
el.:  +34 933674144; fax: +34 933674271.
E-mail address: malgara@parcdesalutmar.cat (M. Algara).
507-1367/$ – see front matter © 2013 Greater Poland Cancer Centre. Publish
ttp://dx.doi.org/10.1016/j.rpor.2013.08.002of new technologies and most relevant clinical trials that
are changing clinical practice in irradiation of breast cancer
patients.
2.  Clinical  and  technological  transition
Radiation oncology is a ﬁeld that has rapidly advanced over
the last century. It holds a rich tradition of clinical care and
evidence-based practice, and more  recently has advanced
with revolutionary innovations in technology and computer la Esperanza, San Jose de la Montana, 12 08024 Barcelona, Spain.
nological advances is the ability to approach any complex
tumor geometry, regardless of shape, with an enhanced ability
to optimize the dose distribution.
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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2.1.  Accelerated  partial  breast  irradiation
APBI can be successfully delivered using different radiation
techniques (IMRT, brachytherapy, arc therapy, etc.) [2]. For
instance, the University of Florence [3] evaluated with a ran-
domized clinical trial the possibility of treating the index
quadrant with IMRT  in a selected group of patients with early-
stage breast cancer. From 2005 to 2008, 259 patients were
randomized and treated. The mean value of the ratio between
the planning target volume and the ipsilateral breast volume
was 21%. The rate of grade 1 acute skin toxicity was 22% and
grade 2 was 19%.
Recent reports from the American Society for Radiation
Oncology (ASTRO) and the Groupe Européen de Curiethérapie-
European Society for Therapeutic Radiology and Oncology
(GEC-ESTRO) have suggested selection criteria for “suitable
patients” who  could receive APBI outside of clinical trials
[4]. Currently, there are 6 ongoing phase III trials. All are
characterized by a signiﬁcant heterogeneity regarding inclu-
sion criteria and stratiﬁcation factors. The French UNICANCER
trial (SHARE; ClinicalTrials.gov identiﬁer NCT01247233) will
randomize 2800 patients in 3 arms: APBI (1 week) using
3-dimensional (3D) conformal radiotherapy, standard radio-
therapy (6.5 weeks), and hypofractionated radiotherapy (3
weeks).
2.2.  Arc  dynamic  therapy
Tomotherapy is a technique capable of delivering a well toler-
ated treatment with high homogeneity and coverage indexes
and high capabilities for sparing the organs at risk [5,6], espe-
cially in patients with anatomically complex breast cancer,
bilateral breast cancer or indication for internal mammary
chain node irradiation. A Spanish report [7] described early
clinical results of tomotherapy treatment in patients with
breast cancer and complex treatment volumes. Ten patients
were treated with tomotherapy between January 2009 and
March 2010. All treatments included daily CT/megavoltage
image guidance. The median homogeneity index was 1.09; and
the median coverage index 0.81. Median V20 Gy and V10 Gy for
ipsilateral lung was 20% and 37.1% respectively. Median V25
and V35 for heart was 15% and 4% respectively. Median dose
for contralateral breast was 7 Gy. Skin acute toxicity was grade
1 in 41.7% and grade 2 in 58.3%.
Versmessen et al. [8] compared Health-related quality
of life (HRQOL) in stage I–II breast cancer patients who
were randomized to receive either conventional radiothe-
rapy or hypofractionated tomotherapy. A total of 121 stage
I–II breast cancer patients who had undergone breast con-
serving surgery or mastectomy were randomly assigned to
receive either conventional radiotherapy or hypofractionated
tomotherapy. Conventional radiotherapy patients received
25 × 2 Gy over 5 weeks, and breast conserving surgery patients
also received a sequential boost of 8 × 2 Gy over 2 weeks.
Hypofractionated tomotherapy patients received 15 × 2.8 Gy
over 3 weeks, and breast conserving surgery patients also
received a simultaneous integrated boost of 15 × 0.6 Gy over
3 weeks. Patients completed the EORTC (European Organiza-
tion for Research and Treatment of Cancer) QLQ-C30 and BR23
questionnaires. Hypofractionated tomotherapy patients hadiotherapy 1 8 ( 2 0 1 3 ) 345–352
a better improvement in global health status and role- and
cognitive-functioning, and a faster recovery from fatigue, than
conventional radiotherapy patients. These results suggested
that a shorter fractionation schedule may reduce the adverse
effects of treatment.
2.3.  Intensity-modulated  radiation  therapy
Intensity-modulated radiation therapy can reduce radiation
dose exposure to normal tissues while maintaining reason-
able target homogeneity [9]. Jin et al. [10] compared the
dosimetry for the left-sided breast cancer treatment using
different radiotherapy techniques. Twenty patients with left
sided breast cancer were planned using ﬁve different radio-
therapy techniques, including: 1) conventional tangential
wedge-based ﬁelds (TW); 2) ﬁeld-in-ﬁeld (FIF) technique; 3)
tangential inverse planning intensity-modulated radiation
therapy (T-IMRT); 4) multi-ﬁeld IMRT (M-IMRT); and 5) volu-
metric modulated arc therapy (VMAT). The planning tumor
volume dose prescribed was 50 Gy and V47.5  95%. The same
dose constraints were used for all ﬁve plans. The planned
volumetric dose of PTV and organ at risk volumes (OARVs)
were compared and analyzed. T-IMRT plan improved the PTV
dose homogeneity index (HI) by 0.02 and 0.03 when compared
to TW plan and VMAT plan, and decreased the V5, V10 and
V20 of all OARVs. However, the high dose volume (30 Gy)
of the OARVs in T-IMRT plan had no statistically signiﬁcant
difference compared with the other two inverse plans. In all
ﬁve plans, the dose volume of coronary artery area showed a
strong correlation to the dose volume of the heart (the cor-
relation coefﬁcients were 0.993, 0.996, 1.000, 0.995 and 0.986
respectively).
In order to increase the workload efﬁciency, a Canadian
group [11] developed a template-based breast IMRT  technique
(TB-IMRT). TB- IMRT provided reduction of planning time com-
pared with conventional breast radiation (14.0 vs 39.0 min,
p < 0.001) and minimized the use of high energy beams, while
providing similar treatment times and equal plans compared
to conventional breast radiation.
2.4.  Brachytherapy
The different indications of breast brachytherapy include all
the breast irradiations focusing on the initial tumor bed (par-
tial irradiation of the breast), such as boost, APBI and second
conservative radiosurgical treatment in case of ipsilateral
in-breast recurrence. Interstitial breast brachytherapy, per-
formed according with the standard rules, remains a major
technique for breast cancer treatment [12].
Partial breast brachytherapy and whole breast irradia-
tion (WBI) has shown similar recurrence-free and overall
survival rates in elderly breast cancer patients [13], even
after adjustment for potential confusing factors. A sample of
29,647 female patients diagnosed with nonmetastatic breast
cancer in 2002–2007 treated with breast-conserving surgery
and radiotherapy was identiﬁed in the Surveillance, Epi-
demiology, and End Results Program-Medicare data set [13].
Recurrence-free survival and overall survival rates did not dif-
fer signiﬁcantly between the two radiation modalities. After
accounting for tumor characteristics, patient characteristics,
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ommunity factors, and comorbidities, the recurrence-free
urvival (hazard ratio, 1.05; 95% conﬁdence interval, 0.90–1.23;
 = 0.5125) and overall survival (hazard ratio, 0.87; 95% con-
dence interval, 0.72–1.04; p = 0.1332) rates were still not
igniﬁcantly different between patients treated with APBI-
rachytherapy and WBI.
Hannoun-Levi et al. [14] prospectively evaluated 40 patients
ged >70 years, T1-2 <30 mm,  and pN0 treated with APBI
y means of high-dose rate-brachytherapy from July 2004 to
pril 2008. The total delivered dose was 34 Gy of 10 fractions
or 5 days. Median Quality Index was 13.3% (1–70%). It was
onsidered acceptable, partially acceptable, and nonaccept-
ble in 10, 28, and 2 patients, respectively. Within 12 months
fter APBI, overall rates of toxicity were 59%, 28%, and 2%
or Grade 1, 2, and 3 events, respectively. Twelve months
fter APBI, 35 patients (87%) achieved excellent/good cosmetic
esult. Compared with baseline values, Activity of Daily Liv-
ng and Instrumental Activity of Daily Living scores remained
nchanged 6 and 12 months after APBI. Therefore, APBI by
eans of high-dose rate-brachytherapy seemed to have an
igniﬁcant negative impact on functional dependence in the
reatment of elderly women with early breast cancer.
.5.  Intraoperative  electron  radiotherapy
lthough this technique is not widely available, IOERT fol-
owed by external beam radiotherapy allows for the delivery
f a high dose to the tumor bed and an adequate dose to
he whole breast [15]. This treatment is feasible, compliance
s high, and the preliminary data on chronic toxicity seems
cceptable. Ivaldi et al. [16] reported the acute and preliminary
ata on late toxicity of a pilot study of boost with IOERT fol-
owed by hypofractionated external beam radiotherapy of the
hole breast performed between June 2004 and March 2007. In
hat study, 108 women with a diagnosis of early-stage breast
ancer were treated with breast-conserving surgery and eval-
ated for late toxicity. During surgery, an IOERT boost of 12 Gy
as administered to the tumor bed. Adjuvant local treatment
as completed with hypofractionated external beam radio-
herapy, consisting of a course of 13 daily fractions of 2.85 Gy
o the whole breast to a total dose of 37.05 Gy. The recorded
ate skin toxicity was Grade 4 in 1 patient (0.9%), Grade 3 in 1
atient, and Grade 2 or less in 106 patients (98.2%).
The Rambam Health Care Campus in Haifa [17] began uti-
izing IOERT in 2006. From April 2006 to September 2010,
1 patients affected by unifocal invasive duct breast carci-
oma 2 cm diameter received wide local resection followed
y IOERT. After a mean follow-up of 36 months, seven patients
eveloped mild breast ﬁbrosis and three suffered from mild
ostoperative infection. Rib fractures were observed in four
atients before routine lead shielding was initiated. Additional
hole-breast irradiation was given to four patients. None of
he patients developed local recurrences or other ipsilateral
ancers. Similarly, no contralateral cancers or distant metas-
ases were observed.
The University of North Carolina [18] conducted a phase
 study of pre-excision IOERT for early-stage breast cancer.
 total of 53 patients ≥48 years of age (median age was 63
ears) with invasive ductal carcinoma, ≤3 cm (median tumor
ize was 1.2 cm), and clinically node-negative received IOERT.therapy 1 8 ( 2 0 1 3 ) 345–352 347
Ultrasound was used to select electron energy and cone size
to cover the tumor plus 1.5- to 2.0-cm lateral margins and 1-
cm-deep margins (90% isodose). Fifteen Gy was delivered with
a Mobetron irradiator, and immediate needle-localized partial
mastectomy followed. Of all patients, 81% were positive for
estrogen receptor or progesterone receptor, 11% were positive
for human epidermal growth factor receptor 2, and 15% were
triple-negative. Also, 42%, 49%, and 9% would have fallen into
the Suitable, Cautionary, and Unsuitable groups, respectively,
of the American Society of Therapeutic Radiation Oncology
consensus statement for accelerated partial breast irradia-
tion. With a median follow-up of 69 months, ipsilateral events
occurred in 8 of 53 patients and the 6-year actuarial rate of
ipsilateral events was 15% (95% conﬁdence interval = 7%-29%).
The crude event rate for Suitable and Cautionary groups was 1
of 22 (5%) and 7 of 26 (27%), respectively. Overall survival was
94.4%, and breast cancer-speciﬁc survival was 100%. There-
fore, the rate of local events was a matter of concern, especially
in the Cautionary group. On the basis of these ﬁndings, pre-
excision IOERT may not provide adequate local control for less
favorable early-stage breast cancers.
In summary, the clinical and technological transition in
breast cancer management experienced in the last decades
offers a diverse array of advanced technologies and treatment
techniques [19]. This variety of options allows us to offer the
more  optimal treatment for each patient according to clinical,
pathological, and patient preferences. The knowledge of this
novel technology should be incorporated in the educational
programs.
3.  EORTC  clinical  trials  and  protocols
Over the last decades, the EORTC Radiation Oncology and
Breast Cancer Groups have conducted a number of practice-
changing randomized phase III studies in the ﬁeld of
loco-regional treatment for breast cancer. These studies have
contributed to building evidence for the ability of RT to
improve loco-regional control, which in turn is translated into
a long-term survival beneﬁt for the patients. This knowledge
highlights the key role that radiation oncology plays in the
multidisciplinary management of cancer patients. Apart from
the trials focussing on loco-regional management, several oth-
ers have been conducted in the ﬁeld of breast cancer focussing
on systemic therapy.
3.1.  Breast  conserving  treatment
One of the randomized clinical trials that has shown equiv-
alent results after breast-conserving therapy (BCT) and after
modiﬁed radical mastectomy (MRM) in stage I and II breast
cancer was EORTC 10801, for which recently an update after
a median follow up of 22.1 years was conducted [20]. Com-
pared with BCT, MRM resulted in a better local control, but did
not signiﬁcantly affect time to distant metastases (which was
the primary endpoint of this trial). Cumulative incidence of
distant metastases and overall survival were similar in both
groups as well. The results were similar for both patients
younger and older than 50 years. The meta-analysis of the
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
348  reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) 345–352
Fig. 1 – Cumulative incidence of ipsilateral breast cancer recurrence according to age. Age (A) ≤40, (B) 41–50, (C) 51–60, and
(D) ≥60 years. HR, hazard ratio; O, occurrences; N, number of patients at risk.
Reproduced with permission from Bartelink H, Horiot JC, Poortmans PM,  et al. Impact of a higher radiation dose on local
control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no
–326boost eortc 22881-10882 trial. J Clin Oncol 2007; 25(22): 3259
conﬁrmed the equivalence of BCT and MRM  with survival as
endpoint [21]. It also demonstrated the need for RT following
lumpectomy to reduce the 5-year local recurrence rate from 26
to 7% and to improve long term survival [22]. Therefore, BCT,
including RT, is accepted as standard care for patients with
early stage breast cancer.
The cosmetic outcome after BCT as given in trial 10801
could often be considered as suboptimal. As a possible rela-
tion with the higher dose (boost) of 25 Gy to the primary tumor
bed was suggested, the subsequent EORTC “Boost-no-boost”
22881/10882 trial investigated the potential impact of the boost
on local control and on treatment complications. This was
done in two parallel prospective randomized trials. After a
microscopically complete resection –as stated by the local
pathologist- 5318 patients were randomized between either
a 16 Gy boost or no boost to the primary tumor bed after 50 Gy
of WBI. This clearly demonstrated that the boost dose sig-
niﬁcantly reduces the local recurrence rate [23]. Whereas the
absolute reduction of the local recurrence rate by nearly 50%
could be demonstrated in all patient subgroups, especially age
turned out to be a very important prognostic factor for the
absolute beneﬁt as the local recurrence rate was demonstrated
to be inversely related to age, as displayed in Fig. 1 [24]. The
presence of DCIS (Ductal carcinoma in situ), tumor size, tumor5.
grade and the administration of adjuvant systemic treatment
were other prognostic factors for local control after BCT [25].
Based on these results, a nomogram was designed and made
available at http://research.nki.nl/ibr/ [26]. In the much smaller
group of 251 patients that was randomized after a micro-
scopically incomplete resection –again as stated by the local
pathologist – between either a 26 Gy boost or a 10 Gy boost, no
signiﬁcant difference could be found [27].
Remarkably, we could not ﬁnd an association between pos-
itive resection margins –as based on central pathology review-
and the risk of local recurrence after BCT [25]. Of note is that
this subgroup analysis only involved patients that were con-
sidered as having a complete excision by the local pathologist.
Apart from disease outcome parameters, we  scored the rate
of ﬁbrosis at the whole breast and at the primary tumor site
at each follow up visit. The boost dose signiﬁcantly increased
the development of ﬁbrosis in both the whole breast and the
boost area. A clear dose-effect relation for ﬁbrosis was seen, as
displayed in Fig. 2 [28]. It remained, however, of minor or mod-
erate severity in most patients. Based on this, we  developed
nomograms  to predict the impact of a boost dose of 16 Gy on
the risk for developing ﬁbrosis at any site in the breast, also
available at the same internet site (http://research.nki.nl/ibr)
[26,28].
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Fig. 2 – Cumulative incidence of moderate or severe ﬁbrosis after 50 Gy whole breast irradiation, followed by no boost or a
boost dose of 10 Gy, 16 Gy and 26 Gy, respectively. O, observed; N,  number of patients at risk; CR, complete resection; IR,
incomplete resection.
Reproduced with permission from Collette S, Collette L. Budiharto T, et al. Predictors of the risk of ﬁbrosis at 10 years after
breast conserving therapy for early breast cancer: a study based on the EORTC trial 22881-10882 “boost versus no boost”.
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Moreover, a cosmetic evaluation was performed with pic-
ures taken at randomization and every 3 years thereafter. The
osmetic result was scored as excellent to good in 86% of the
atients without a boost and in 71% of the patients with a
oost [29]. Apart from the boost, other independent predictive
actors for a worse cosmetic outcome were a location of the
rimary tumor in the lower quadrants of the breast, the size
f the excision specimen, the occurrence of a breast infection
nd/or a hematoma, and larger tumor size [30]. An inhomoge-
eous dose distribution of WBI  was also found to negatively
nﬂuence the risk of developing ﬁbrosis, as was also demon-
trated by Donovan et al. [31].
.2.  DCIS
ORTC Trial 10853 contributed to the knowledge about the
alue of WBI  after lumpectomy for DCIS [32]. The EBCTCG
nalysis, including this trial, demonstrated that after lumpec-
omy and RT the number of recurrences are about halved, for
s well in situ as for invasive recurrences [33]. The number of
atients needed to treat to avoid 1 recurrence within 10 years
rom treatment is 7. Notwithstanding this, the annual recur-
ence rate in these trials, which were mostly conducted in the
0’s and early 90’s, still amounted to an annual rate of 1.3%, of
hich half are invasive. Nowadays, results are demonstrated
o be better.
A special case is Paget disease of the nipple, for which
ittle evidence exist about the optimal treatment approach.
he prospective phase 2 registration trial EORTC 10873 did
ot succeed to collect enough patients for bringing a highlevel of evidence for a conservative treatment composed of
a complete excision of the nipple–areolar complex including
possible underlying disease followed by WBI  [34]. Thanks to
this work, this treatment can be considered as a valuable alter-
native to mastectomy, leaving mastectomy for patients with
more  extensive disease or recurrence after RT.
3.3.  Quality  assurance
Quality assurance (QA) in radiation oncology has focussed
greatly on trials in breast cancer. While the EORTC trial 10801
demonstrated equivalent overall survival rates for up to more
than 20 years after treatment, a signiﬁcant difference in local
control was seen between the participating centers [35]. This
has lead to an extensive QA program for the subsequent
EORTC trial 22881/10882 [36]. Probably as a consequence of
this, the variance in outcome for the participating patients
did not vary from one center to another [37]. Since then, a QA
program that is adapted to the design and the technical com-
plexity became a standard procedure for all EORTC trial which
have RT as a component of the treatment [38,39].
3.4.  Challenges  and  failures
The outcome of breast cancer improved a lot thanks to
ever-continuing progress in diagnosis and in locoregional
and systemic treatment approaches. With the decrease in
“events”, it become progressively more  time consuming to
accrue and follow enough patients to demonstrate a clini-
cally relevant beneﬁt. Moreover, when ﬁnally presented and
350  reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) 345–352
Table 1 – Risk categories for locoregional relapses after mastectomy and axillary clearance. Ax LN + = involved axillary
lymph nodes.
Risk category Low Intermediate High
Tumor stage T1-2 T1-2 T3-4
Number of Ax LN+ 0 1–3 >3
Grade 1–2 3
Vascular invasion – +
Histology Ductal Lobular
Risk <10% 10–20% >20%
Reproduced with permission from Poortmans P. Educational review. Evidence based radiation oncology: breast cancer. Radiother Oncol 2007;
84: 84–101.
Table 2 – Indication for irradiation of the different target volumes after mastectomy and axillary clearance as well as for
regional RT in the framework of BCT. Yes = evidence and generally accepted; Yes? = evidence but not generally accepted;
No? = limited evidence, however advocated by some.
Risk category Low Intermediate High
Thoracic wall No?  Yes? Yes
Supraclavicular No? Yes? Yes
Internal mammary No Yes? Yes?
Axilla No No No
 Evide
studies, we  can expect that the management of the axilla will
continue to change markedly in the near future.
Fig. 3 – Local breast recurrence rate in three consecutive
trials on breast conserving therapy from 1980 until 2012.Reproduced with permission from Poortmans P. Educational review.
84: 84–101.
published, part of the treatment given to the participating
patients might be considered as outdated. This can complicate
the acceptance of the results of the trials by part of the mul-
tidisciplinary team involved in breast cancer management.
Unfortunately, EORTC did not manage to bring the
LAMANOMA trial (10974/22002) to a good end due to poor
accrual of patients [40]. However, the main question of the
trial, whether breast conserving treatment with RT with
or without surgery following primary systemic treatment
for locally advanced breast cancer can be considered as a
valuable option still remains of interest for patient with non-
inﬂammatory breast cancer after a good clinical response to
systemic treatment. Due to a lack of interest and/of fund-
ing, the EORTC did also not manage to set up or contribute
to a trial investigating the place of accelerated partial breast
irradiation in low risk patients and to a trial further elaborat-
ing on the boost no boost trial but then focussing on young
patients. Luckily enough, both efforts turned out to be suc-
cessful in another setting and with a major contribution of
RT departments that are dedicated members of the EORTC.
The results obtained in the Young Boost trial, not yet split up
per randomization group, clearly demonstrate to what extent
local control in early stage breast cancer after breast conserv-
ing therapy has improved over the years (Fig. 3 [41]). After the
very successful.
AMAROS trial [42] (Adjuvant Management of the Axilla,
Radiotherapy of Surgery), EORTC did not succeed in setting
up a successive trial, due to a number of reasons including
the presentation of the results of other trials, ever again chal-
lenging the proposed trial designs.
3.5.  Other  trialsAfter the presentation and publication of new data on
the selection of target volumes to be treated, we  are now
eagerly waiting for the results of the large prospective EORTCnce based radiation oncology: breast cancer. Radiother Oncol 2007;
22922/10925 trial that investigated to value of elective irradia-
tion of the internal mammary  and supraclavicular lymph node
regions for stage 1–3 breast cancer patients after lumpectomy
and axillary lymph node dissection or after modiﬁed radical
mastectomy. An early analysis did not show an increased level
of toxicity [43]. In Table 1, a division in three risk categories for
locoregional relapse after mastectomy and axillary clearance
is shown. Based on this, Table 2 is a proposed summary of the
indications for radiotherapy for the different target volumes
[44].
A prospective randomized EORTC 10981-22023 trial,
AMAROS [42] was conducted to compare the treatment
approaches for patients with involved sentinel lymph nodes.
The results of this trial will be presented very soon. Together
with the presentation and publication of the results of otherReproduced with permission from Bartelink H, Bourgier C,
Elkhuizen P. Has partial breast irradiation by IORT  or
brachytherapy been prematurely introduced into the clinic?
Radiother Oncol 2012; 104(2): 139–142.
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.6.  Current  studies
urrently, EORTC participates to the intergroup trial led by the
ustralian Trans-Tasman Radiation Oncology Group (TROG)
rimarily investigating the value of a boost to the primary
umor bed in the framework of breast conserving treatment
or patients with DCIS. In this trial, an optional randomiza-
ion between the traditional and a hypofractionated radiation
chedule is included as well. Accrual is going very well.
nother intergroup trial, led by the Medical Research Coun-
il, SUPREMO (Selective Use of Postoperative Radiotherapy
fter Mastectomy) randomizes patients with 1–3 involved
ymph nodes, and pT2pN0 tumors with grade 3 tumors and/or
ymphovascular invasion between chest wall irradiation and
ollow-up [45]. Accrual will be completed this year. The trial
lso includes cardiac, quality of life, health economic and bio-
ogical substudies.
.7.  Possible  future  trials
urrently, we  are discussing the integration of partial breast
rradiation into primary systemic treatment for patients with
ocally or loco-regionally advanced breast cancer that are pos-
ibly candidates for breast conserving treatment after tumor
olume reduction. This ﬁts into the principle of moving par-
ial breast irradiation to the preoperative stage to decrease
he amount of nontarget breast volume included, improve tar-
et volume deﬁnition. It also obviates the new challenges for
arget volume deﬁnition after oncoplastic surgery.
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